Symposia

Varcoe: New Meta-Analysis Shows No Difference in Mortality with Paclitaxel Coated vs Uncoated Devices in Patients with CLI

02/24/2020

Ramon L. Varcoe, MBBS, MS, FRACS, PhD, discusses his group's publication of a meta-analysis reporting the risk of all-cause mortality after treatment with paclitaxel-coated devices vs uncoated controls in patients with chronic limb-threatening ischemia (CLTI).

The conclusions of this new meta-analysis differ from those of the controversial Katsanos et al meta-analysis published in January 2020.

Reference

Dinh K, Gomes ML, Thomas SD, Paravastu SCV, Holden A, Schneider PA, Varcoe RL. Mortality after paclitaxel-coated device use in patients with chronic limb-threatening ischemia: a systematic review and meta-analysis of randomized controlled trials. J Endovasc Ther. 2020 Feb 18:1526602820904783. doi: 10.1177/1526602820904783. [Epub ahead of print]

Stay in the Know

Vascular Disease Management Newsletter

News

Late-Breaking Trials

Final Round of Late-Breaking Clinical Trial Results Announced at VIVA24

11/06/2024

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...

The VIVA Foundation, a...

11/06/2024

Vascular Disease Management

Late-Breaking Trials

Third Round of Late-Breaking Clinical Trial Results Announced at VIVA24

11/05/2024

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...

The VIVA Foundation, a...

11/05/2024

Vascular Disease Management

Late-Breaking Trials

Second Round of Late-Breaking Clinical Trial Results Announced at VIVA24

11/04/2024

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...

The VIVA Foundation, a...

11/04/2024

Vascular Disease Management

Late-Breaking Trials

First Round of Late-Breaking Clinical Trial Results Announced at VIVA24

11/04/2024

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...

The VIVA Foundation, a...

11/04/2024

Vascular Disease Management

Image-Guided Therapy

Philips Enrolls First Patient in U.S. Clinical Trial for Innovative Integrated Single-Device to Treat Peripheral Artery Disease

11/04/2024

With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...

With a unique world-first...

11/04/2024

Vascular Disease Management

Pulmonary Embolism

Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism

11/04/2024

QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...

QUADRA-PE study will evaluate...

11/04/2024

Vascular Disease Management

Peripheral Arterial Disease

FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease

11/04/2024

MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...

MOUNTAIN VIEW, Calif. – November...

11/04/2024

Vascular Disease Management

Patient Awareness

Baby Boomers Beware: More Americans Than Ever Before Now at Higher Risk for Common Blood Vessel Diseases

10/31/2024

New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...

New survey reveals nearly one in...

10/31/2024

Vascular Disease Management

DCB

SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery

10/30/2024

Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...

Data from the prospective,...

10/30/2024

Cath Lab Digest

Zilver Vena Stent

Zilver Vena Stent Shows High Patency Across All Patient Groups in Three-Year Clinical Study

10/29/2024

Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...

Bloomington, Ind. — Cook...

10/29/2024

Vascular Disease Management

Varcoe: New Meta-Analysis Shows No Difference in Mortality with Paclitaxel Coated vs Uncoated Devices in Patients with CLI

Stay in the Know

News

Specialties

Events

Year Round Education

HMP Global Products